Maria Papadaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria Papadaki has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan Kirk
Center for Cardiovascular Research, Department of Medicine, University of Chicago, Chicago, IL (M.M.D., J.A.K.).
2 shared publications - Steven Baxter Marston
National Heart and Lung Institute, Imperial College London, London, United Kingdom
2 shared publications - Abigail Nagle
Department of Laboratory Medicine and Pathology (A.N., J.D.), University of Washington, Seattle, WA
1 shared publication - Amy Li
School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia.
1 shared publication - Andrew E. Messer
Imperial College London, London, UK
1 shared publication Andrew Messer
1 shared publication
Latest Publications
- 14 August 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (5)
Contractility Drives Cardiomyocyte Maturation and the Response to Nanopatterns
BACKGROUND: Understanding the mechanisms of cardiomyocyte development is critical for fulfilling the potential of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). Although myocyte development is known to depend on internal and external mechanical cues, further investigation is required to understand the contributions of different signals and how they are integrated together to generate an adult cardiomyocyte. Here, we address this gap by examining the role of calcium-activated contractility in sarcomere formation and maturation and its influence on the iPSC-CM response to nanopatterns. METHODS: We generated iPSCs with homozygous D65A cTnC (cardiac troponin C) substitutions. This engineered cTnC cannot bind to calcium at site II, resulting in tropomyosin blocking strong myosin binding to the thin filament and inhibiting sarcomere contraction. The iPSCs were differentiated into cardiomyocytes and matured in culture over 60 days. Cells were characterized via imaging, metabolic assays, and calcium transient analysis. Proteomes were examined using mass spectrometry throughout differentiation and maturation. We also replated partially matured cardiomyocytes onto nanopatterned surfaces to investigate how external mechanical signals affect maturation in contractile versus noncontractile cells. RESULTS: Surprisingly, we found that sarcomeres formed in the D65A cTnC cardiomyocytes, though these sarcomeres were underdeveloped and disorganized. The D65A cardiomyocytes also exhibited significant proteomic maturation defects and abnormal calcium transients. Replating the noncontractile cardiomyocytes onto nanopatterns improved several structural and proteomic maturation metrics. In contrast, wildtype maturation did not benefit from the introduction of nanopatterns. CONCLUSIONS: Calcium-activated contractility is dispensable for sarcomerogenesis but critical for cardiomyocyte maturation. In noncontractile, D65A cTnC cardiomyocytes, nanopatterns enhanced maturation, suggesting that external mechanical cues may partially compensate for defective contractility. However, nanopatterns did not facilitate wildtype maturation, suggesting that maturity may reduce the efficacy of nanopatterns. In addition to these novel findings, these mass spectrometry data sets cataloging iPSC-CM maturation represent a useful resource for the cardiovascular research community.
- 14 August 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (5)
Contractility Drives Cardiomyocyte Maturation and the Response to Nanopatterns
BACKGROUND: Understanding the mechanisms of cardiomyocyte development is critical for fulfilling the potential of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). Although myocyte development is known to depend on internal and external mechanical cues, further investigation is required to understand the contributions of different signals and how they are integrated together to generate an adult cardiomyocyte. Here, we address this gap by examining the role of calcium-activated contractility in sarcomere formation and maturation and its influence on the iPSC-CM response to nanopatterns. METHODS: We generated iPSCs with homozygous D65A cTnC (cardiac troponin C) substitutions. This engineered cTnC cannot bind to calcium at site II, resulting in tropomyosin blocking strong myosin binding to the thin filament and inhibiting sarcomere contraction. The iPSCs were differentiated into cardiomyocytes and matured in culture over 60 days. Cells were characterized via imaging, metabolic assays, and calcium transient analysis. Proteomes were examined using mass spectrometry throughout differentiation and maturation. We also replated partially matured cardiomyocytes onto nanopatterned surfaces to investigate how external mechanical signals affect maturation in contractile versus noncontractile cells. RESULTS: Surprisingly, we found that sarcomeres formed in the D65A cTnC cardiomyocytes, though these sarcomeres were underdeveloped and disorganized. The D65A cardiomyocytes also exhibited significant proteomic maturation defects and abnormal calcium transients. Replating the noncontractile cardiomyocytes onto nanopatterns improved several structural and proteomic maturation metrics. In contrast, wildtype maturation did not benefit from the introduction of nanopatterns. CONCLUSIONS: Calcium-activated contractility is dispensable for sarcomerogenesis but critical for cardiomyocyte maturation. In noncontractile, D65A cTnC cardiomyocytes, nanopatterns enhanced maturation, suggesting that external mechanical cues may partially compensate for defective contractility. However, nanopatterns did not facilitate wildtype maturation, suggesting that maturity may reduce the efficacy of nanopatterns. In addition to these novel findings, these mass spectrometry data sets cataloging iPSC-CM maturation represent a useful resource for the cardiovascular research community.
- Open Access
- 12 January 2022
- Published by Elsevier in Biophysical Journal
- Vol. 121 (4) , 565-574
Myofibril orientation as a metric for characterizing heart disease
- 12 January 2022
- Published by Elsevier in Biophysical Journal
- Vol. 121 (4) , 565-574
Open AccessMyofibril orientation as a metric for characterizing heart disease
- Open Access
- 18 October 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (20)
Diabetes with heart failure increases methylglyoxal modifications in the sarcomere, which inhibit function
Patients with diabetes are at significantly higher risk of developing heart failure. Increases in advanced glycation end products are a proposed pathophysiological link, but their impact and mechanism remain incompletely understood. Methylglyoxal (MG) is a glycolysis byproduct, elevated in diabetes, and modifies arginine and lysine residues. We show that left ventricular myofilament from patients with diabetes and heart failure (dbHF) exhibited increased MG modifications compared with nonfailing controls (NF) or heart failure patients without diabetes. In skinned NF human and mouse cardiomyocytes, acute MG treatment depressed both calcium sensitivity and maximal calcium-activated force in a dose-dependent manner. Importantly, dbHF myocytes were resistant to myofilament functional changes from MG treatment, indicating that myofilaments from dbHF patients already had depressed function arising from MG modifications. In human dbHF and MG-treated mice, mass spectrometry identified increased MG modifications on actin and myosin. Cosedimentation and in vitro motility assays indicate that MG modifications on actin and myosin independently depress calcium sensitivity, and mechanistically, the functional consequence requires actin/myosin interaction with thin-filament regulatory proteins. MG modification of the myofilament may represent a critical mechanism by which diabetes induces heart failure, as well as a therapeutic target to avoid the development of or ameliorate heart failure in these patients.
- 18 October 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (20)
Open AccessDiabetes with heart failure increases methylglyoxal modifications in the sarcomere, which inhibit function
Patients with diabetes are at significantly higher risk of developing heart failure. Increases in advanced glycation end products are a proposed pathophysiological link, but their impact and mechanism remain incompletely understood. Methylglyoxal (MG) is a glycolysis byproduct, elevated in diabetes, and modifies arginine and lysine residues. We show that left ventricular myofilament from patients with diabetes and heart failure (dbHF) exhibited increased MG modifications compared with nonfailing controls (NF) or heart failure patients without diabetes. In skinned NF human and mouse cardiomyocytes, acute MG treatment depressed both calcium sensitivity and maximal calcium-activated force in a dose-dependent manner. Importantly, dbHF myocytes were resistant to myofilament functional changes from MG treatment, indicating that myofilaments from dbHF patients already had depressed function arising from MG modifications. In human dbHF and MG-treated mice, mass spectrometry identified increased MG modifications on actin and myosin. Cosedimentation and in vitro motility assays indicate that MG modifications on actin and myosin independently depress calcium sensitivity, and mechanistically, the functional consequence requires actin/myosin interaction with thin-filament regulatory proteins. MG modification of the myofilament may represent a critical mechanism by which diabetes induces heart failure, as well as a therapeutic target to avoid the development of or ameliorate heart failure in these patients.
- Open Access
- 2 November 2016
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 7, 508
The Importance of Intrinsically Disordered Segments of Cardiac Troponin in Modulating Function by Phosphorylation and Disease-Causing Mutations
Troponin plays a central role in regulation of muscle contraction. It is the Ca2+ switch of striated muscles including the heart and in the cardiac muscle is physiologically modulated by PKA-dependent phosphorylation at Ser22 and 23. Many cardiomyopathy-related mutations affect Ca2+ regulation and/or disrupt the relationship between Ca2+ binding and phosphorylation. Unlike the mechanism of heart activation, the modulation of Ca2+-sensitivity by phosphorylation of the cardiac specific N-terminal segment of TnI (1-30) is structurally subtle and has proven hard to investigate. The crystal structure of cardiac troponin describes only the relatively stable core of the molecule and the crucial mobile parts of the molecule are missing including TnI C terminal region, TnI (1-30), TnI (134-149) (‘inhibitory’ peptide) and the C-terminal 28 amino acids of TnT that are intrinsically disordered. Recent studies over the years have been performed to answer this matter by building structural models of cardiac troponin in phosphorylated and dephosphorylated states based on peptide NMR studies. Now these have been updated by more recent concepts derived from molecular dynamic simulations treating troponin as a dynamic structure. The emerging model confirms the stable core structure of troponin and the mobile structure of the intrinsically disordered segments. We will discuss how we can describe these segments in terms of dynamic transitions between a small number of states with the probability distributions being altered by phosphorylation and by HCM or DCM-related mutations that can explain how Ca2+-sensitivity is modulated by phosphorylation and the effects of mutations.
- 2 November 2016
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 7, 508
Open AccessThe Importance of Intrinsically Disordered Segments of Cardiac Troponin in Modulating Function by Phosphorylation and Disease-Causing Mutations
Troponin plays a central role in regulation of muscle contraction. It is the Ca2+ switch of striated muscles including the heart and in the cardiac muscle is physiologically modulated by PKA-dependent phosphorylation at Ser22 and 23. Many cardiomyopathy-related mutations affect Ca2+ regulation and/or disrupt the relationship between Ca2+ binding and phosphorylation. Unlike the mechanism of heart activation, the modulation of Ca2+-sensitivity by phosphorylation of the cardiac specific N-terminal segment of TnI (1-30) is structurally subtle and has proven hard to investigate. The crystal structure of cardiac troponin describes only the relatively stable core of the molecule and the crucial mobile parts of the molecule are missing including TnI C terminal region, TnI (1-30), TnI (134-149) (‘inhibitory’ peptide) and the C-terminal 28 amino acids of TnT that are intrinsically disordered. Recent studies over the years have been performed to answer this matter by building structural models of cardiac troponin in phosphorylated and dephosphorylated states based on peptide NMR studies. Now these have been updated by more recent concepts derived from molecular dynamic simulations treating troponin as a dynamic structure. The emerging model confirms the stable core structure of troponin and the mobile structure of the intrinsically disordered segments. We will discuss how we can describe these segments in terms of dynamic transitions between a small number of states with the probability distributions being altered by phosphorylation and by HCM or DCM-related mutations that can explain how Ca2+-sensitivity is modulated by phosphorylation and the effects of mutations.
- 1 January 2015
- Published by Elsevier in Biophysical Journal
- Vol. 108 (2) , 447a
Molecular Dynamics Studies on Phosphorylated and Unphosphorylated Cardiac Troponin
- 1 January 2015
- Published by Elsevier in Biophysical Journal
- Vol. 108 (2) , 447a
Molecular Dynamics Studies on Phosphorylated and Unphosphorylated Cardiac Troponin
- 1 January 2015
- Published by Elsevier in Biophysical Journal
- Vol. 108 (2) , 361a-362a
Epigallocatechin-3-Gallate Reverses the Defects in Modulation of Ca2+-Sensitivity by Troponin I Phosphorylation Caused by Hypertrophic and Dilated Cardiomyopathy Mutations in Cardiac Muscle
- 1 January 2015
- Published by Elsevier in Biophysical Journal
- Vol. 108 (2) , 361a-362a
Epigallocatechin-3-Gallate Reverses the Defects in Modulation of Ca2+-Sensitivity by Troponin I Phosphorylation Caused by Hypertrophic and Dilated Cardiomyopathy Mutations in Cardiac Muscle